Cytek Biosciences, Inc. (CTKB) revenue
Cytek Biosciences, Inc. (CTKB) reported revenue of $201.49M in fiscal 2025 (the year ended December 31, 2025). That is 0.5% higher than the $200.45M of fiscal 2024. Figures as of 17 Nov 2026, 21:45 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2025
- $201.49M
- Change on fiscal 2024
- +0.5%
- Growth, 5 years
- +16.8% a year
- Highest on record
- $201.49Mfiscal 2025
- Lowest on record
- $92.84Mfiscal 2020
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Cytek Biosciences, Inc. revenue, in more detail
Over the five fiscal years to 2025 revenue grew at a compound 16.8% a year. Across the 6 fiscal years on record (2020–2025), the highest was $201.49M in fiscal 2025 and the lowest $92.84M in fiscal 2020.
Revenue by fiscal year
Cytek Biosciences, Inc. revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2025 | $201.49M | 0.5% up | |
| 2024 | $200.45M | 3.9% up | |
| 2023 | $193.02M | 17.7% up | |
| 2022 | $164.04M | 28.2% up | |
| 2021 | $127.95M | 37.8% up | |
| 2020 | $92.84M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Cytek Biosciences, Inc., figure by figure
- Cytek Biosciences, Inc. market cap
- Cytek Biosciences, Inc. earnings
- Cytek Biosciences, Inc. earnings per share (EPS)
- Cytek Biosciences, Inc. P/E ratio
- Cytek Biosciences, Inc. P/S ratio
- Cytek Biosciences, Inc. P/B ratio
- Cytek Biosciences, Inc. free cash flow
- Cytek Biosciences, Inc. operating margin
- Cytek Biosciences, Inc. dividend
- Cytek Biosciences, Inc. shares outstanding
- Cytek Biosciences, Inc. total debt
- Cytek Biosciences, Inc. cash on hand
- Cytek Biosciences, Inc. total assets
- Cytek Biosciences, Inc. return on equity (ROE)
- Cytek Biosciences, Inc. return on invested capital (ROIC)
Cytek Biosciences, Inc. (CTKB) overview: price, valuation and scorecard
Cytek Biosciences, Inc. revenue: questions and answers
What is Cytek Biosciences, Inc.'s revenue?
Cytek Biosciences, Inc. (CTKB) reported revenue of $201.49M in fiscal 2025 (the year ended December 31, 2025). That is 0.5% higher than the $200.45M of fiscal 2024.
What is the growth rate of Cytek Biosciences, Inc.'s revenue?
Over the five fiscal years to 2025 revenue grew at a compound 16.8% a year.
What are the highest and lowest revenue figures on record for Cytek Biosciences, Inc.?
Across the 6 fiscal years on record (2020–2025), the highest was $201.49M in fiscal 2025 and the lowest $92.84M in fiscal 2020.
How is Cytek Biosciences, Inc.'s revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Cytek Biosciences, Inc. (CTKB) revenue”, data as of 17 November 2026. https://funkfolio.com/stock/CTKB/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.